



PRESS RELEASE

Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016

Thursday December 17, 2015 at 5:45 PM (CET)

Lyon, December 15th, 2015 - Adocia (Euronext Paris: FR0011184241 - ADOC) will provide a business update for investors on a conference call to be held:

Thursday December 17, 2015

at 5:45pm (CET)

***(the dial-in number and the pin codes will be available on Adocia's website
Wednesday December 16th 2015)***

The transcript will be available in French on Adocia's website

www.adocia.com

Adocia's team will discuss 2015 key achievements and present an overview of current plans and priorities for 2016. **G rard Soula**, President and CEO, together with **Olivier Soula**, R&D Director and Deputy General Manager; **Val rie Danaguezian**, Financial Director and **R mi Soula**, Director of Business Development & Intellectual Property, will conduct the call.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia's proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. To learn more about Adocia, please visit us at www.adocia.com.



For more information please contact:

<p>Adocia G�rard Soula Chairman and CEO contactinvestisseurs@adocia.com Tel.: +33 4 72 610 610</p>	<p>Adocia Press Relations ALIZE RP Caroline Carmagnol and Florence Portejoie caroline@alizerp.com adocia@alizerp.com Tel.: + 33 1 44 54 36 61</p>
--	---